Your opportunity to receive
an ophthalmology research or fellowship grant
To fund research initiatives in order to advance scientific understanding of retinal diseases
To encourage ophthalmologists to develop skills and to support future thought leaders
To improve treatment outcomes and patient quality of life through management of retinal diseases
February 1, 2019
Letter of Intent (LOI) submission deadline
Applicants notified of the decision;
Full Proposal forms distributed to successful applicants
May 15, 2019
Full Proposal submission deadline
Applicants notified of the decision
"GOAP presents a wonderful opportunity to seek funding for your innovative research. Since its inception in 2012, 70 clinical investigators and basic researchers from around the globe have utilized their GOAP-awarded grants to advance the field of ophthalmology, with the ultimate goal of improving eye care and preserving vision for patients throughout the world. We look forward to receiving your grant application submissions."
Professor Quan Dong Nguyen
(Co-chair of the Grants Review and Awards Committee)
About Global Ophthalmology Awards Program (GOAP)
- Established by Bayer in 2012
- Designed to support innovative research in retinal disease globally, awarding grants of up to US$50,000
- Since 2012, 70 grants totalling US$3.5million have been awarded to support a range of innovative ophthalmology research projects
Who is Bayer?
The Bayer Group is a global enterprise with core competencies in the fields of healthcare, nutrition and high-tech materials. Bayer's aim is to discover and manufacture products that will improve human and animal health worldwide. Find more information at pharma.bayer.com.
The Global Ophthalmology Awards Program (GOAP) is an initiative instituted by Bayer that supports research and training in retinal ophthalmology with the aim of advancing the scientific understanding and clinical management of ophthalmic disorders. Through research and training grants the program seeks to provide opportunities for ophthalmology healthcare professionals that will ultimately lead to improved treatment and management for the world’s ophthalmology patients.
The GOAP demonstrates Bayer’s commitment to the global ophthalmic disorders community and to advancing state-of-the-art ophthalmic care.